LDS/Medical Tests/Cytochrome P450 3A4 (CYP3A4) Genotyping

Cytochrome P450 3A4 (CYP3A4) Genotyping

Cytochrome P4503A4 (CYP3A4) belongs to the superfamily of cytochrome P450 enzymes. CYP3A4 is mainly expressed in the liver and to a lesser extent in the small intestines. CYP3A4 and CYP3A5 have overlapping substrate specificity. This contribution of CYP3A5 enzyme in the overall metabolism is smaller than CYP3A4 and the overall CYP3A metabolic capacity is not expected to affect the majority of drug substrates except for narrow therapeutic index drugs.

Similar to other CYP450 enzymes, CYP3A4 is an important enzyme responsible for metabolism of many clinical drugs. It is estimated that 50-60% of clinical drugs used today are metabolized by CYP3A4, including acetaminophen, codeine, cyclosporine A, diazepam, and erythromycin. The FDA recommends, but does not require, genetic testing of CYP3A4 prior to initiating or reinitiating treatment with fluvoxamine, and avoiding using CYP3A4 together with ticagrelor.

CYP3A4 is also important for the metabolism of steroid hormones, which has been extensively used for hormone replacement therapy. CYP3A4 has also been implicated in the etiology of neoplasms including prostate cancer and leukemia through activation of procarcinogens, including aflatoxin B1, PAHs, NNK, and 6-aminochrysene.

The CYP3A4 assay is used for detection of 5 different single point polymorphisms or gene variations in CYP3A4 gene: *1B (-392A>G), *2 (15713T>C), *3 (23171T>C), *12 (21896C>T), *17 (15615T>C). The CYP3A4 *1B variant results in an enzyme with a moderately decreased activity. The CYP3A4 *2, *3, *12 and *17 are also considered decreased activity alleles. The genotype-phenotype relationship is not well established and in general individuals are either CYP3A4 normal or intermediate metabolizers. No poor metabolizers have been reported to date.

It should be noted that grapefruit inhibits this enzyme and there have been deaths in individuals taking certain medications who consumed grapefruit resulting in lowered drug metabolizing activity and subsequent overdose.

  • Determining therapeutic strategy for therapeutics that are metabolized by the CYP450 3A4 gene product
  • Monitor and manage pain management drug therapy
  • Monitor and manage atorvastatin, simvastatin and lovastatin therapy
  • As an aid in therapy of prostate cancer and leukemias

The CYP3A4 \*1B variant is the most studied and if detected results in an enzyme with a moderately decreased activity. It occurs in 55% of African Americans, 3-5% of Caucasians and <1% of Asians.

The CYP3A4 \*2, \*3, \*12 and \*17 if detected are also considered decreased enzyme activity.

The genotype-phenotype relationship for CYP3A4 is not well established and individuals are predicted to have either a CYP3A4 normal or intermediate metabolic capacity.

No poor metabolizers have been reported to date.

Cytochrome P450 3A4 metabolizes these drug classes:

  • Macrolide antibiotics such as erythromycin; antiarrhythmics like quinidine
  • Benzodiazepine sedatives including such as diazepam and midazolam
  • Immune system modulators like cyclosporine
  • HIV-directed antiviral agents such as ritonavir and saquinavir
  • The prokinetic agent cisapride; antihistamines such as astemizole and terfenidine
  • Calcium channel blockers including nifedipine and verapamil
  • HMG-CoA reductase inhibitors like lovastatin

CYP3A4 has also been shown to metabolize a broad diversity of other drugs from the opioid analgesic alfentanyl to stimulants like caffeine and non-benzodiazepine hypnotics like zolpidem.

The following is a list of major inhibitors that compete with other drugs for a particular enzyme thus affecting the optimal level of metabolism of the substrate drug which in many cases affect the individual's response to that particular medication, e.g. making it ineffective.

  • A Strong inhibitor is one that causes a > 5-fold increase in the plasma AUC values or more than 80% decrease in clearance. This include: indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole,nefazodone, saquinavir, telithromycin
  • A Moderate inhibitor is one that causes a > 2-fold increase in the plasma AUC values or 50-80% decrease in clearance. This include: aprepitant, erythromycin, fluconazole, grapefruit juice, verapamil, diltiazem
  • A Weak inhibitor is one that causes a > 1.25-fold but < 2-fold increase in the plasma AUC values or 20-50% decrease in clearance such as cimetidine, amiodarone, chloramphenicol, boceprevir, ciprofloxacin, delaviridine, diethyl, dithiocarbamate, fluvoxamine, gestodene, imatinib, mibefradil, mifepristone, norfloxacin, norfluoxetine, starfruit, telaprevir, voriconazole

CYP3A4 \*1/\*1 (Normal metabolizer)

Allele Specific Primer Extension (ARMS) by Real-time Polymerase chain reaction (PCR), Next generation sequencing (NGS), Conventional Sequencing.

Whole blood collected in lavender top tube (EDTA) or any anticoagulant collection devices, buccal swab, saliva. 

Stability

  • Ambient: 5 days
  • Refrigerated: 7 days
Drug toxicity testing if available, other CYP450 Gene Variations (CYP3A5, CYP2D6, CYPC9, CYPC19).
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login